ANCA Vasculitis Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

(Albany, US) September 10, 2026- DelveInsight’s “ANCA Vasculitis Pipeline Insight 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the ANCA Vasculitis Pipeline? @ https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight

Key Takeaways from the ANCA Vasculitis Pipeline Report

• On September 04, 2026, Novartis Pharmaceuticals initiated a phase 2 study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA).
• On September 02, 2026, Fate Therapeutics conducted a Phase 1/2, open-label trial designed to evaluate the safety, pharmacokinetics (PK), anti-B-cell activity, and clinical activity of FT839 in participants with moderate-to-severe ANCA-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc).
• DelveInsight’s ANCA Vasculitis Pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for ANCA Vasculitis treatment.
• The leading ANCA Vasculitis companies include Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
• Promising ANCA Vasculitis therapies include Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone, Rituximab, Mycophenolate Mofetil, and others.

Want to know which companies are leading innovation in ANCA Vasculitis? @ ANCA Vasculitis Clinical Trials Assessment

The ANCA Vasculitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The ANCA Vasculitis Pipeline Report also highlights the unmet needs with respect to the ANCA Vasculitis.

ANCA Vasculitis Overview

Antineutrophilic cytoplasmic antibody (ANCA) associated Vasculitis are a heterogeneous group of rare autoimmune conditions that causes an inflammation of blood vessels with various manifestations. It includes three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis. Signs and symptoms of ANCA vasculitis include fatigue, fever, weight loss, and muscle or joint pain. It can cause specific organ involvement, leading to respiratory issues like cough or shortness of breath and kidney problems such as blood in the urine. Skin manifestations, including rashes or ulcers, may also occur. Additionally, patients may experience nerve damage, resulting in numbness or weakness, and gastrointestinal symptoms like abdominal pain or diarrhea.

ANCA Vasculitis Emerging Drugs Profile

• BDB-001: Staidson (Beijing) Biopharmaceutical

BDB-001 is an investigational anti-complement C5a monoclonal antibody being developed by Staidson (Beijing) Biopharmaceuticals for the treatment of ANCA-associated vasculitis (AAV). By selectively neutralizing C5a, a key mediator of complement activation that drives neutrophil priming, inflammation, and vascular injury in AAV, BDB-001 aims to suppress disease activity while potentially reducing patients’ dependence on high-dose glucocorticoids. The therapy has previously demonstrated an acceptable safety profile and pharmacodynamic inhibition of circulating C5a in early clinical studies, supporting its continued development. BDB-001 is currently being evaluated in a Phase III for the treatment of ANCA Associated Vasculitis.

• Sparsentan: Travere Therapeutics

Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

If you’re tracking ongoing ANCA Vasculitis Clinical trials, this press release is a must-read @ ANCA Vasculitis Treatment Drugs

The ANCA Vasculitis Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of ANCA Vasculitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ANCA Vasculitis Treatment.
• ANCA Vasculitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ANCA Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ANCA Vasculitis market.

ANCA Vasculitis Companies

Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.

ANCA Vasculitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the ANCA Vasculitis Pipeline Report covers it all @ ANCA Vasculitis Market Drivers and Barriers, and Future Perspectives

Scope of the ANCA Vasculitis Pipeline Report

• Coverage- Global
• ANCA Vasculitis Companies- Staidson (Beijing) Biopharmaceutical, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co., Ltd., and others.
• ANCA Vasculitis Therapies- Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Cyclophosphamide, Glucocorticoids, Prednisolone and Rituximab, Mycophenolate Mofetil, Avacopan, and others.
• ANCA Vasculitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• ANCA Vasculitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the ANCA Vasculitis Treatment landscape in this detailed analysis @ ANCA Vasculitis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. ANCA Vasculitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. ANCA Vasculitis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. BDB-001: Staidson (Beijing) Biopharmaceutical
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Sparsentan: Travere Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. ANCA Vasculitis Key Companies
21. ANCA Vasculitis Key Products
22. ANCA Vasculitis- Unmet Needs
23. ANCA Vasculitis- Market Drivers and Barriers
24. ANCA Vasculitis- Future Perspectives and Conclusion
25. ANCA Vasculitis Analyst Views
26. ANCA Vasculitis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anca-vasculitis-pipeline-insight